Charity Number 1119105 Company Number 05951118 (England and Wales)
BOWEL & CANCER RESEARCH
TRUSTEES’ REPORT, INDEPENDENT EXAMINER’S REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
BOWEL & CANCER RESEARCH CONTENTS FOR THE YEAR ENDED 31 DECEMBER 2020
| CONTENTS | PAGES |
|---|---|
| Charity Information | 1 |
| Trustees’ Report | 2 – 10 |
| Independent Examiner’s Report | 11 - 12 |
| Statement of Financial Activities | 13 |
| Balance Sheet | 14 |
| Cash Flow Statement | 15 |
| Notes to the Financial Statements | 16 - 31 |
BOWEL & CANCER RESEARCH REERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY ITS TRUSTEES AND ADVISORS FOR THE YEAR ENDED 31 DECEMBER 2020
TRUSTEES Mr Paul Reynolds (Chairman) Mr Richard Pertwee (appointed 25/05/2021) Ms Asha Senapati (appointed 25/05/2021) Professor Marilena Loizidou (resigned 27/05/2021) Mr Charles Bueno De Mesquita (resigned 04/05/2020) Mr Chris Ellyatt (resigned 25/11/2020) Mr Jeremy C Hitchins (resigned 25/11/2020) Professor Charles Knowles BChir PhD FRCS (resigned 24/09/2020) Mrs Kathryn Pretzel Shiels (resigned 27/05/2021) PRESIDENT Professor Sir Norman Williams MS FRCS FMed Sci FRCP FRCP (Edin) FRCA FDS (Hon) FACS (Hon) FRCSI (Hon) FRCSEd (Hon) CHIEF EXECUTIVE Martine Gabbitass Acting CEO and Company Secretary (appointed 30/11/2019) Rebecca Porta (appointed Chief Executive 27/4/2020) CHARITY NUMBER 1119105 COMPANY NUMBER 05951118 (England and Wales) PRINCIPAL ADDRESS National Bowel Research Centre AND REGISTERED 1[st] Floor, Abernethy Building OFFICE 2 Newark Street London E1 2AT INDEPENDENT AUDITOR Tara Westcott FCCA Crowe U.K. LLP 4[th] Floor, St James House St James’ Square Cheltenham Gloucestershire GL50 3PR BANKERS CAF Bank 25 Kings Hill Avenue Kings Hill, West Malling Kent ME19 4TA Flagstone Investment Managers 17[th] Floor, New Zealand House 80 Haymarket London SW1Y 4TE INVESTMENT MANAGERS Quilter Cheviot Senator House 85 Queen Victoria Street London EC4V 4AB WEBSITE www.bowelresearchuk.org
1
BOWEL & CANCER RESEARCH TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
Bowel & Cancer Research is a leading bowel research authority. We fund and promote world class, innovative research and invest in the next generation of researchers through a dedicated PhD studentship programme.
CHAIR’S STATEMENT
In November 2019 Bowel & Cancer Research announced its intention to combine with the charity Bowel Disease Research Foundation. With a shared commitment to investing in our scientific and medical communities, we believe that a cure for bowel cancer and effective treatments to mitigate, or entirely eradicate, other bowel diseases are entirely possible in the future.
Collectively our two charities have more than 50 years’ experience and have awarded grants totalling £9 million over the last ten years towards research into bowel cancer and other bowel diseases. This research has improved our understanding of these diseases and identified new ways to treat and manage them.
Despite the impact and many challenges we faced with the COVID-19 pandemic, we remained committed to bringing together the two charities and the launch of our new charity, Bowel Research UK, CIO registered number 1186061 on the 29th September 2020 was a great success. The launch offered the opportunity to celebrate the important contribution the founding charities have made to improving the outlook for those diagnosed and living with bowel cancer and other bowel diseases alongside announcing our new research priorities and our commitment to radically changing the landscape and ultimately the outlook for current and future generations.
Supported by a wide range of stakeholders including the public, patients and their families, the research community, Parliamentarians, decision makers, strategic partners and the media, we announced our commitment to investing £1 million in innovative, cutting edge research over the next eighteen months and in the longer term, to funding life changing research. By researching cutting edge treatments and investing in the best science, we're saving and improving people's lives.
I am pleased to report that £182,610 had been invested in research and PhD programmes at the end of 2020, £320,000 in January 2021 and a further £325,000 awarded as part of our Inaugural Grants round in July 2021. Funding will enable important developments in clinical practice. a better quality of life and improvements in patient outcomes.
The launch of Bowel Research UK offers hope to the 42,000 people diagnosed every year with bowel cancer in the UK and the 1million plus living with other bowel diseases such as the inflammatory bowel diseases Crohn’s disease and Ulcerative Colitis. We look forward to an exciting future and to radically changing the landscape.
2
/44Y4 Bowel& rtrY%I Cancer *>l#Y- Research BOWEL & CANCER RESEARCH TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2020 CHAIR'S STATEMENT (¢onllnued) Bowel & Cancer Research has made an Important contribution to research, and I would like to lake this opportunlty to thank the research community, supporters. patlents and their families, and all those involved in its success over many years. It is thanks to you that we have been able to achieve so much and wlll continue to do so in the future. I would particularly like to thank all the staff and all the Trustees who have worked so hard and made such a big impact over the years. Paul Reynolds Chairman Dated: 28 September 2021
BOWEL & CANCER RESEARCH TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
WHY DOES THE CHARITY EXIST?
Funding Research – The National Bowel Research Centre
Bowel & Cancer Research is primarily a research funder; it is unique in having a base within The National Bowel Research Centre (NBRC) within the Blizard Institute at Queen Mary University of London.
Its relationship with the NBRC gives the charity a unique perspective across all bowel pathologies and interventions. Its funding support created the NBRC in 2012 and its relationship with the NBRC extends across research funding and patient involvement in research. The charity values its close relationship with the NBRC and will continue to look at opportunities to build upon our achievements and impact going forward.
Funding Research – Grant Giving
We are proud of our many achievements and the important contribution we make in furthering innovative, cutting edge research into bowel cancer and other bowel diseases.
During the year we worked with colleagues at Bowel Disease Research Foundation (BDRF) to bring together our research programmes, establish our research priorities and ensure the relevant systems and protocols were in place to ensure the quality of the research we consider, to advance understanding of bowel cancer and other bowel diseases and maximize the impact of our funding. This included:
-
The appointment of a new Grants Committee to consider grant applications and make recommendations for funding
-
The appointment our first Director of Research and PPI to oversee and lead the research programme
-
Establishing research priorities to include diseases with significant impact, poorer outcomes and low awareness
-
A monitoring system for our grant programmes through the grants management system,
-
Communicating with all current grant holders and key stakeholders regarding the launch of Bowel Research UK.
Research Archive - Bowel Research UK : Bowel Research UK
4
BOWEL & CANCER RESEARCH TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
WHAT IS THE CHARITY DOING TO COMBAT BOWEL CANCER AND BOWEL DISEASE?
Fundraising
During 2020 the COVID-19 pandemic led to many restrictions on day to day life which has led to the first decrease in our year on year growth. Our events income dropped significantly with mass participation events and community fundraising unable to take place. Fundraising staff of both Bowel & Cancer Research and BDRF focused on three key areas during this time: building the new website and resources, supporter communications and developing a programme of fundraising activities for 2021 and beyond including virtual events. As with many charities we will continue to ensure a diverse range of funding streams and programmes are employed going forward.
During the year our fundraising income was £507,606 ( 2019 18 months - £1,728,078 ). Costs of fundraising, including salaries, totaled £83,625 ( 2019 18 months- £304,377 ). As a charity we have limited overheads so that we can invest as much as possible in research and growing our charity.
The most significant drop in our income relates to Trust income £89,450 (2019 18 months - £564,634). Many Trusts diverted their funds to support the pandemic crisis and the majority of awards were given to charities supporting work in communities and the charity NHS together.
We have been notified of various legacies over this period totaling £189,323 which will enable us to invest in more ground breaking studies. Legacies play such an important part in the work that we do and have funded many research grants over the years. We would like to thank everybody who thinks of us in their will by leaving a legacy and strive to achieve great work with their generosity.
2020 saw much of the country locked down and with restrictions throughout the year. Our Events and Challenges income of £74,993 is a remarkable achievement in light of this and we applaud all of our great supporters for raising so much in very difficult circumstances.
Following the launch of Bowel Research UK in September 2020 all fundraising activity is now managed and delivered by Bowel Research UK. All research grants will now be awarded by Bowel Research UK.
Fundraising note
Fundraising activities for the charity are carried out by charity staff with assistance from volunteers with the running of specific fundraising events. We only use established and recognised agencies (3[rd] party fundraisers) for our recruitment of payroll givers – individuals who donate through their pay. We do not employ street or other face-to-face fundraisers through agencies. All fundraising activities are monitored by the Fundraising, Marketing and Communications Committee, with oversight by members of the governing body.
5
BOWEL & CANCER RESEARCH TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
WHAT IS THE CHARITY DOING TO COMBAT BOWEL CANCER AND BOWEL DISEASE? (continued)
No complaints relating to fundraising activities have been received by the charity during this financial period. However, the charity has in place procedures that would be followed in the event of a complaint being received with the initial response being the responsibility of the Chief Executive. Any continuing issues would then be passed to the governing body to determine what further action might be required.
We are registered with the Fundraising Regulator, demonstrating our commitment to good fundraising practice. We are committed to abide by the Fundraising Regulator’s Code of Fundraising Practice and to the Fundraising Promise and we are authorised to use the Fundraising Regulator badge on our fundraising materials.
We are very aware of our obligations to the public in this area and we are vigilant in our fundraising activities to ensure that there is no intrusion on people’s privacy or any undue pressure applied to vulnerable people.
Collaborations
The charity welcomes and values opportunities to collaborate and partner with other charities and organisations who have similar aims and objectives. As Bowel Research UK we look forward to engaging with charities working in the area of bowel cancer and other bowel diseases including Pseudo Obstruction Research Trust (P.O.R.T), with whom we have a long standing relationship.
PLANS FOR THE FUTURE
The launch of Bowel Research UK on the 29th September 2020 offered the opportunity to mark the important contribution the founding charities have made to improving the outlook for those diagnosed and living with bowel cancer and bowel disease alongside announcing our commitment to changing radically the landscape and ultimately the outlook for current and future generations. Bowel Research UK will take forward a cutting edge research programme which will include the launch of a new research strategy and significant investment in priority areas.
As part of these plan’s Bowel & Cancer Research annual accounts have not been prepared on a going concern basis.
6
BOWEL & CANCER RESEARCH TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
FINANCIAL REVIEW AND RESERVES POLICY
Income
Voluntary income during the period totalled £507,606 (18 months 2019 - £1,728,078). With income from Government grants and investments included, total incoming resources was £532,799 (2019 - £1,774,477).
Details of the charity’s sources of income for the year can be seen on page 19.
Investments
During the period, the charity’s investment income was £19,170 (2019 - £46,399).
2020 was a year for the most part one would like to forget and it was certainly a turbulent one for investments. However, having an investment policy setting out clear parameters between short and longterm reserves provided the Charity with financial resilience. The merits of being invested in a welldiversified portfolio and the decision to invest with Quilter Cheviot and into their specialist charity fund has proven a good decision. The investment in the Global Income and Growth Fund for Charities delivered a total return of 10.6% over the year against the Funds composite benchmark of 3.2%. It is also worth noting that this is well ahead of inflation (CPI at 0.9%).
The performance is overseen by the Finance and Investment Committee, which meets quarterly. The Investment policy statement sets clear guidelines for the investment manager and these are reviewed at least annually.
The charity reported a capital gain of £16,020 (2019 – gain of £68,853 ) during the year.
We have placed a significant amount of cash that we hold on deposit with Flagstone, an online cash management system. This allowed us to place money across a number of financial institutions while maintaining protection given by financial services compensation scheme (FSCS). As a result, we have managed to increase the amount of interest from around 0.4% to over 1% which equates to an uplift of over £7,000 per annum.
Reserves
On the 30[th] September 2020, the Trustees of Bowel & Cancer Research and Bowel Disease Research Foundation launched Bowel Research UK a CIO, charity number 1186061. The reserves of Bowel & Cancer Research were transferred to Bowel Research UK with the exception of accrued income which all relate to legacies left to Bowel & Cancer Research. The reserves policy of the new charity has been reviewed in light of market situation around the pandemic.
Sources of Funds
The charity relies upon voluntary income and receives no income from statutory contracts. Our fundraising strategy has been developed to deliver a broad base of voluntary income which is not over reliant on any single source of fundraising or any single donor. During the year the Charity signed up the Coronavirus Job Retention scheme
7
BOWEL & CANCER RESEARCH TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
STRUCTURE, GOVERNANCE AND MANAGEMENT
Constitution
The charity is a Company Limited by Guarantee, its governing document is the Memorandum and Articles of Association, dated 29 September 2006, and it is a registered charity (No. 1119105). The Company was formed to take over the operations of the charitable trust of the same name with the charity number 328667. The company number is 05951118.
Bowel Research UK became a member during 2020.
Structure
Bowel Research UK as the ultimate member of the charity has a new constitution and all governance procedures have been reviewed and amended as necessary. All sub committees operate as part of the parent charity; full details can be found within their annual accounts.
Organisational Management
During 2020 all members of staff moved over to Bowel Research UK by way of Transfer of Undertaking (Protection of Employment) Regulations 2006.
Risk Management
The charity risk management is managed by the Trustees of Bowel Research UK.
8
BOWEL & CANCER RESEARCH TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
OBJECTS, AIMS AND PUBLIC BENEFIT
OBJECTS
The general charitable objects as stated in the Memorandum and Articles of Association are:
a) The conduct of medical research into the causes of cancer and other bowel related diseases in all its forms and the publication of such research;
b) The relief of any person who is or has been a sufferer from cancer or any similar disease, and to provide assistance to the relatives or close associates of any such person; and
c) Any other charitable purpose according to the law of England and Wales including the making of donations to any charitable institutions with similar objects.
AIMS
Bowel Research UK is funding life changing research into bowel cancer and other bowel diseases. Every year over 16,000 people die from bowel cancer in the UK and over a million suffer from bowel disease. By researching cutting edge treatments and investing in the best science, we’re saving and improving people’s lives. Let’s end bowel cancer and bowel disease.
PUBLIC BENEFIT
In November 2019 the Trustees announced their intention to combine forces with the charity Bowel Disease Research Foundation. With a shared commitment to investing in our scientific and medical communities and combining expertise whilst reducing overheads and operating costs, we believe that the public will benefit from enhanced research programmes and that a cure for bowel cancer and effective treatments to mitigate, or entirely eradicate, other bowel diseases are entirely possible in the future. The Trustees have given due consideration to the Charity Commission’s published guidance on the Public Benefit requirement under the Charities Act 2011.
RELATED PARTIES
Relationships and transactions with related parties are recorded as they occur. A register of declared interests is maintained by the Board and reviewed at each meeting. Please see note 19 of these financial statements for details of relationships and transactions with related parties during the year.
9
144Y4 Bowel& rtrYII Canr ¢>trY- Research BOWEL & CANCER RESEARCH TRUSTEES, REPORT FOR THE YEAR ENDED 31 DECEMBER 2020 STATEMENT OF TRUSTEES RESPONSIBILITIES The Trustees (who are also Directors of 8owel & Cancer Research for the purposes of company lawl are responsible for Pfeparing the Trustees. Annual Report and the financial slatements in accordance wtth applicable law and United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards). Company law requires the Trustees to prepare financlal statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a Irue and fair view of the state of affairs of the Charitable Company and of the incoming resources and application of resources, including the income and expenditure. of the Charltable Company for that period. In preparing these financial statements. the Trustees are required to: seleth suitable accounting policies and then apply them consislentl observe the methods and principles in the Chartties SORP.. m8kejudgements and estimates that are reasonable and prudeit state whether applicable UK accounting standards have been followed, subject to any materlal departures disclosed and explalned in the financial statements,. and prepare the financial statements on Ihe going concern basis unless tt Is inappropriate to presume that the charitable company will continue in business. The Trustees are responsible for keeplng adequate accounting records ihat are sufflclent to show and explain the charitys transactions, disclose with reasonable accuracy at any tlme the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charitys constitution. They are also responsible for safeguarding the assets of the charty and hence for tsking reasonable steps for the prevention and detection of fraud and other irregularities. In preparing this report. the Trustees have taken advantage of the Small companies exemptions provided by section 415A ofthe Companies Ad 2006. This report was approved by the Trustee$ on 28 September 2021 and signed on its behalf by Paul Re Ids hèlr of Trust¢•s) 10
BOWEL & CANCER RESEARCH INDEPENDENT EXAMINER’S REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
Independent examiner's report to the trustees of Bowel & Cancer Research
I report to the charity trustees on my examination of the accounts of the company for the year ended 31 December 2020, which are set out on pages 12 to 31.
This report is made solely to the charitable company’s trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and the charitable company’s trustees as a body in accordance with section 154 of the Charities Act 2011. My independent examiner’s work has been undertaken so that I might state to the charitable company’s trustees those matters I am required to state to them in an independent examiner’s report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charitable company, the charitable company’s members as a body and the charitable company’s trustees as a body for my independent examiner’s work, for this report, or for the opinions I have formed.
Responsibilities and basis of report
As the charity’s trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’).
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity’s accounts as carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.
Independent examiner’s statement
Since the Company’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
-
accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
-
the accounts do not accord with those records; or
-
the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a ‘true and fair’ view which is not a matter considered as part of an independent examination; or
-
the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].
The financial statements have been prepared on a basis other than going concern as the trade and assets were transferred to Bowel Research UK on 30th September 2020.
11
BOWEL & CANCER RESEARCH NDEPENDENT EXAMINER’S REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Tara Westcott FCCA Crowe U.K. LLP 4[th] Floor St James House St James’ Square Cheltenham Gloucestershire GL50 3PR
Date: 29 September 2021
12
BOWEL & CANCER RESEARCH STATEMENT OF FINANCIAL ACTIVITIES (Incorporating an Income and Expenditure Account) FOR THE YEAR ENDED 31 DECEMBER 2020
| Year | 18 month period | ||||
|---|---|---|---|---|---|
| Unrestricted | Restricted | ended | 31 December | ||
| funds | funds | 31 | 2019 | ||
| December | Total | ||||
| 2020 | |||||
| Total | |||||
| Note | £ | £ | £ | £ | |
| INCOME FROM | |||||
| Donations and legacies | 4 | 429,806 | 77,800 | 507,606 | 1,728,078 |
| Government Grants | 5 | 6,023 | - | 6,023 | - |
| Investments | 6 | 19,170 | **- ** | 19,170 | 46,399 |
| Total | 454,999 | 77,800 | 532,799 | 1,774,477 | |
| EXPENDITURE ON: | |||||
| Raising funds | 7 | 83,625 | - | 83,625 | 304,377 |
| Charitable activities | 7 | 238,497 | 15,000 | 253,497 | 1,519,908 |
| Total | 322,122 | 15,000 | 337,122 | 1,824,285 | |
| Net gains on investments | 12 | 16,020 | - | 16,020 | 68,853 |
| Net income | 148,897 | 62,800 | 211,697 | 19,045 | |
| Transfers between funds | 16B | 77,800 | (77,800) | **- ** | **- ** |
| Transfer to Bowel Research | 22 | ||||
| UK | (411,577) | (140,450) | (552,027) | **- ** | |
| Net movement in funds total | (184,880) | (155,450) | (340,330) | **- ** | |
| Reconciliation of funds | |||||
| Total funds brought forward | 16B/C/D | 880,381 | 155,450 | 1,035,831 | 1,016,786 |
| Total funds carried forward | 16B/C/D | 695,501 | - | 695,501 | 1,035,831 |
The notes on pages 16 to 31 form part of these financial statements.
13
/44Y4 Bowel & CanT *>trY- Rv6earch BOWEL & CANCER RESEARCH BALANCE SHEEr AS AT 31 DECEMBER 2020 Note 2020 2079 FIXED ASSErs Tangible assets Invesiments 2932 12 792,243 CURRENT ASSETS Debtors Cash at bank and in hand 13 695,501 697.713 695,501 7,779,306 CREDITORS.. amounts falling due within one year 14 NET CURRENT ASSETS TOTAL ASSETS LESS CURRENT LIABILITIES 695,501 1.576,336 CREDITORS.. amounts falling due after more than one year 15 TOTAL ASSErs FUNDS OF THE CHARITY Restricted funds Unrestricted funds Designated Funds 16B 16C 16D 75S450 424, 784 695,501 The charity was entitled to exemption from audit under section 477 of the Companies Act 2006. The members have not required the company lo obtain an audit forthe year in question in accordance wsth section 476 of The Companies Act 2006. The Trustees acknowledge their responslbllities for complying with the requirements of the act with respect lo accounting records and the preparation of financial statements. The financlal statement5 have been prepared In 8ccordance wtth provisions applicable to companies subject to the small companies, regirne. The financial statements were approved and authorised for issue by the Trustees and were slgned on 28th September 2021 on their behalf by UIR Company Number- 05951118 The notes on pages 16 to 31 form part of these financial statements. 14
BOWEL & CANCER RESEARCH STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2020
| OWEL & CANCER RESEARCH TATEMENT OF CASH FLOWS OR THE YEAR ENDED 31 DECEMBER 2020 |
|||
|---|---|---|---|
| Year ended | 18 month | ||
| 31 December | period ended | ||
| 2020 | 31 Dec 2019 | ||
| Total | Total | ||
| Note | |||
| £ | £ | ||
| Cash flows from operating activities: | |||
| Net cash used in operating activities | 17 | (1,356,601) | (56,206) |
| Cash flows from investing activities | |||
| Dividends and interest from investments | 19,170 | 46,399 | |
| Purchase of tangible fixed assets | (574) | (2,690) | |
| Fixed assets transferred to Bowel Research UK | 2,508 | - | |
| Purchase of Investments | (793,295) | (440,962) | |
| Movements on investment cash balance | - | 4,277 | |
| Proceeds from sale of investments | 793,295 | 657,202 | |
| Transfer of investments to Bowel Research UK | 805,331 | - | |
| Transfer of net assets to Bowel Research UK | (552,027) | - | |
| Net cash provided by investing activities | 274,408 | 264,226 | |
| Change in cash and cash equivalents in the | |||
| reporting period | 18 | (1,082,193) | 208,020 |
| Cash and cash equivalents at the beginning of the | |||
| reporting period | 18 | 1,082,193 | 874,173 |
| Cash and cash equivalents at the end of the | |||
| reporting period | 18 | - | 1,082,193 |
The notes on pages 16 to 31 form part of these financial statements
15
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
1. CHARITY INFORMATION
Bowel & Cancer Research is registered in England as an incorporated charity limited by guarantee with Companies House (registered no. 05951118) and Charity Commission (registered no. 1119105). The address of its registered office is 1[st] Floor, Abernethy Building, 2 Newark Street, London E1 2AT.
2. ACCOUNTING POLICIES
(a) Basis of accounting
The financial statements have been prepared under the historical cost convention with the exception of investments which are included at market value. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 March 2018 - (Charities SORP (FRS 102)) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), Companies Act 2006 and Charities Act 2011.
Bowel & Cancer Research meet the definition of a public benefit entity under FRS 102.
- (b) Accounting period
We draw attention to the change in the financial period during 2019. The Trustees made the decision to extend the period to 18 months and a period end date of December 2019 in light of the decision to merge with Bowel Disease Foundation. The accounting date was changed with Companies house and the charity commission.
- (c) Going concern
We draw attention to note 22 to the financial statements which explains that the Trustees intend to liquidate the Charity over the coming months and therefore do not consider it to be appropriate to adopt the going concern basis for accounting in preparing the financial statements. Accordingly, the financial statements have been prepared on a basis other than going concern.
(d) Income
Income received by way of donations and legacies is recognised in the Statement of Financial Activities once the charity has entitlement to the resources and once the Trustees have probability that the resource will be received and when the monetary value can be measured with sufficient reliability.
Income from investments is included in the year in which it is receivable.
Donated services have been included and expensed at full cost where the charity feels that this best shows the benefit to the charity that has been received without payment.
For cut-off purposes, legacy income is recognised when there is a grant of probate, the executors have established there are sufficient funds to distribute income from the estate, the legacy can be valued with reasonable accuracy and any conditions attached to the legacy have been met or are within the control of the charity.
16
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
2. ACCOUNTING POLICIES (continued)
(d) Income (continued)
Grants from government bodies are received for specific projects/costs and are recognised in accordance with their individual terms and conditions. Income is recognised when the Charity has entitlement to the funds which is when any performance conditions are met, it is probable that the income will be received and the amount can be reliably measured. Grant income will be deferred if received in advance of meeting performance conditions or if the funder specifically states that the income may be spent in a future accounting period.
(e) Expenditure
Expenditure is recognised in the year which it is incurred.
Expenditure on raising funds are those incurred in seeking voluntary contributions and raising investment income.
Charitable activities are those costs incurred in funding research posts, by way of reimbursement of salary, other employment costs, materials and laboratory costs.
Governance costs are those incurred in connection with constitutional and statutory requirements of the charity and are included within support costs.
Expenditure is allocated to the category to which they relate or where relevant are apportioned based on time spent.
Termination payments are calculated based on contractual basis and reflect length of service of the employee.
Irrecoverable VAT is charged against the category of expenditure for which it was incurred.
(f) Grants
Expenditure on all grants is recognised once the charity has made an unconditional commitment to pay the grant and this is communicated to the beneficiary. The maximum period that small grants are given is generally 18 months. Our PhD funding program now in its third year, awards grants of £75,000 over 3 years where applicants are successful.
(g) Investments
Investments are included at market value at the Balance Sheet date. Gains on investments are calculated as the difference between the market value at the current year end and the market value at the previous year end (or date of acquisition if purchased in the year). Movements in the year are recognised in the Statement of Financial Activities.
(h) Debtors
Other debtors and accrued income are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.
(i) Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions.
17
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
2. ACCOUNTING POLICIES (continued)
(j) Creditors
Creditors are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably.
(k) Funds
The restricted funds comprise donations and grants given by the donors for specific purposes.
Unrestricted funds are expendable at the discretion of the Trustees in furtherance of the objects of the charity. The details of the restrictions can be found in note 16B.
Designated funds are ring-fenced funds set aside by the Trustees for specific purposes.
(l) Taxation
As a registered charity, the entity is entitled to taxation exemptions on all its income and gains, properly applied for its charitable purposes.
(m) Pensions
The charity makes regular contributions to the individual pension plans on behalf of certain staff. These are a direct charge in the Statement of Financial Activities in the year that contributions are due.
(n) Financial instruments
The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value. Investments are recognised at fair value.
(o) Fixed Assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. No depreciation is charged in the year of acquisition, and is allocated based on the cost of assets less their residual value over their estimated useful lives.
Depreciation is provided on the following basis: Computer Equipment – 33% straight line.
(p) Significant estimates and judgements
Preparation of the financial statements requires management to make significant judgements and estimates. The items in the financial statements where these judgements and estimates have been made include:
• Impairment of debtors
The charity makes an estimate of other debtors. When assessing the impairment of debtors, management considers factors including the current credit rating of the debtor, the ageing profile of debtors and historical experience.
• Accounting for legacies
Please refer to accounting policy (d)
18
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
3. STATEMENT OF FINANCIAL ACTIVITIES FOR THE 18 MONTH PERIOD ENDED 31 DECEMBER 2019
| 2019 | ||||
|---|---|---|---|---|
| Unrestricted | Restricted | 2019 Total | ||
| funds | funds | funds | ||
| Note | £ | £ | £ | |
| INCOME FROM: | ||||
| Donations and legacies | 4 | 1,365,263 | 362,815 | 1,728,078 |
| Investments | 6 | 46,399 | - | 46,399 |
| Total | 1,411,662 | 362,815 | 1,774,477 | |
| EXPENDITURE ON: | ||||
| Raising funds | 7 | 302,377 | 2,000 | 304,377 |
| Charitable activities | 7 | 1,110,373 | 409,535 | 1,519,908 |
| Total | 1,412,750 | 411,535 | 1,824,285 | |
| Net gain on investments | 12 | 68,853 | - | 68,853 |
| Net income/(expenditure) | 67,765 | (48,720) | 19,045 | |
| Transfer between funds | 16B | 75,000 | (75,000) | - |
| Net movement in funds | 142,765 | (123,720) | 19,045 | |
| Reconciliation of funds: | ||||
| Total funds brought forward | 16B/C/D | 737,616 | 279,170 | 1,016,786 |
| Total funds carried forward | 16B/C/D | 880,381 | 155,450 | 1,035,831 |
19
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
| EL & CANCER RESEARCH S TO THE FINANCIAL STATEMENTS THE YEAR ENDED 31 DECEMBER 2020 |
||
|---|---|---|
| ONATIONS AND LEGACIES | 18 month | |
| Year ended | period ended | |
| 31 December | 31 December | |
| 2020 | 2019 | |
| £ | £ | |
| Donations | 318,283 | 1,104,252 |
| Legacies | 189,323 | 623,826 |
| 507,606 | 1,728,078 |
4. DONATIONS AND LEGACIES
The charity received Google Ad funding during the year, valued at £65,614 ( 2019: £103,066 ), this enables the charity to make use of Google Adwords via a Gift in Kind agreement. The Google Adwords funding allows for free marketing and positioning on the google search engine and improves visibility for the charity. This is recognised within income as a donation and an equivalent charge is recognised in support costs.
5. INCOME FROM GOVERNMENT GRANTS
| 5. | INCOME FROM GOVERNMENT GRANTS | ||
|---|---|---|---|
| 18 month | |||
| Year ended | period ended | ||
| 31 December | 31 December | ||
| 2020 | 2019 | ||
| £ | £ | ||
| Coronavirus Job Retention Scheme | 6,023 | - | |
| 6,023 | - | ||
| 6. | INCOME FROM INVESTMENTS | ||
| 18 month | |||
| Year ended | period ended | ||
| 31 December | 31 December | ||
| 2020 | 2019 | ||
| £ | £ | ||
| Interest received | 7,443 | 14,545 | |
| Dividends received | 11,727 | 31,854 | |
| 19,170 | 46,399 |
20
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
7. ANALYSIS OF TOTAL EXPENDITURE
| Raising Funds Charitable Expenditure Funding of research posts and National Centre Governance |
Staff Costs £ 32,571 92,638 - 125,209 |
Other Direct Costs £ 51,054 14,970 - 66,024 |
Support Costs £ 118,734 1,906 120,640 |
Year ended 31 December 2020 £ 18 month period ended 31 December 2019 £ Grants Total Total £ £ £ - 83,625 304,377 25,249 251,591 1,484,703 - 1,906 35,205 25,249 337,122 1,824,285 |
|
|---|---|---|---|---|---|
ANALYSIS OF GOVERNANCE COSTS
| ANALYSIS OF GOVERNANCE COSTS | ||
|---|---|---|
| 18 month period | ||
| Year ended | ended | |
| 31 December | 31 December | |
| 2020 | 2019 | |
| £ | £ | |
| Audit and accountancy | 436 | 7,323 |
| Insurance | - | 4,769 |
| Investment Managers | - | 11,054 |
| IT equipment and support | 90 | 2,931 |
| Depreciation | 998 | 999 |
| Other costs | 382 | 211 |
| 1,906 | 27,287 |
21
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
| 8. GRANTS COMMITTED IN THE YEAR | 8. GRANTS COMMITTED IN THE YEAR | 18 month | ||
|---|---|---|---|---|
| Year | period ended | |||
| ended | 31 December | |||
| 31 December | 2019 | |||
| 2020 | £ | |||
| £ | ||||
| Grants to Institutions | ||||
| CovidSurg | 10,000 | - | ||
| ReCaP Project | 5,249 | - | ||
| Leeds MedTech NIHR joint funding | 10,000 | - | ||
| Phd - Atypical BRAF mutations in colorectal cancer | - | 74,993 | ||
| Phd - Assessing the function of resident memory T cells in IBD. - |
75,000 | |||
| Phd - New treatment for advanced Bowel cancer | - | 74,659 | ||
| Phd - Modelling genetic differences in bowel cancer tumours | - | 75,000 | ||
| Phd - Patient Experience of Locally Recurrent Rectal Cancer | - | 65,896 | ||
| Unravelling tumour-immune interactions in bowel cancer | - | 45,000 | ||
| Harnessing MRI for the diagnosis of chronic intestinal pseudo | - |
49,544 | ||
| obstruction | ||||
| IBD in BME | - | 49,875 | ||
| Developing neurons: their potential for tissue repair | - | 50,000 | ||
| Sonic therapy and nanotechnology to treat bowel cancer | - | 49,825 | ||
| A new approach to gastroparesis and nausea | - | 50,000 | ||
| Phd - Predicting patient response to rectal cancer treatment | - | 75,000 | ||
| Phd – response to Oxipilation | - | 74,998 | ||
| Building resilience to Ulcerative Colitis | - | 75,000 | ||
| Vascular invasion in colorectal cancers | - | 75,000 | ||
| Exploring Epigenetic Changes in Diverticular Sepsis | - | 23,408 | ||
| Pilato Project | - | 5,880 | ||
| Decoy bypass surgery | - | 70,000 | ||
| Projects cancelled by Grant Holder | - | (54,836) | ||
| Total | 25,249 | 1.004,242 | ||
| 18 month | ||||
| Year ended | period ended | |||
| 31 December | 31 December | |||
| 2020 | 2019 | |||
| £ | £ | |||
| Reconciliation of grants payable | ||||
| Commitments at 1 January 2020 | 1,459,488 | 909,676 |
||
| Commitments made in the period | 25,249 | 1,004,242 | ||
| Grants paid during the period | (432,244) | (454,430) | ||
| Grant Commitments transferred to Bowel Research UK | (1,052,493) | _- _ | ||
| Commitments at 31 December 2020 | - | 1,459,488 |
Full details regarding grants payable are available on our website www.bowelresearchuk.org.
22
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
9. ANALYSIS OF STAFF COSTS
| ALYSIS OF STAFF COSTS | ||
|---|---|---|
| 18 month | ||
| Year ended | period ended | |
| 31 December | 31 December | |
| 2020 | 2019 | |
| £ | £ | |
| Wages and salaries | 116,135 | 366,115 |
| Social security costs | 3,291 | 34,755 |
| Other costs – pension costs | 5,783 | 10,926 |
| 125,209 | 411,796 | |
| The average headcount of persons employed by the | 18 month | |
| charitable company during the year was as follows: | Year ended | period ended |
| 31 December | 31 December | |
| 2020 | 2019 | |
| £ | £ | |
| Management/Fundraising/Research | 5 | 7 |
| The number of employees whose remuneration exceeded | ||
| £60,000 was nil | ||
| £160,000- £170,000 (note 18 month period) | - | 1 |
The 18 month period ended 31 December 2019 included redundancy payments.
The Trustees received no remuneration nor were they reimbursed for any of their expenses in either accounting period.
| 18 month | ||
|---|---|---|
| Year ended | period ended | |
| 31 December | 31 December | |
| 2020 | 2019 | |
| £ | £ | |
| The remuneration of the key management personnel was: | 56,627 | 244,683 |
| This includes the salaries of the CEO and the Finance Manager. |
23
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
10. INDEPENDENT EXAMINER’S FEES
| 18 month period | |||
|---|---|---|---|
| Year ended | ended | ||
| 31 December | 31 December | ||
| 2020 | 2019 | ||
| £ | £ | ||
| Examiner’s Fees: Independent Examination | 1,750 | - | |
| Audit | - | 4,500 | |
| 11. | TANGIBLE FIXED ASSETS | 2020 | |
| £ | |||
| Cost | |||
| At 1 January 2020 | 3,931 | ||
| Additions | 574 | ||
| Transferred to Bowel Research UK | (4,505) | ||
| At 31 December 2020 | - | ||
| Depreciation | |||
| At 1 January 2020 | 999 | ||
| Charge for the year | 998 | ||
| Transferred to Bowel Research UK | (1,997) | ||
| At 31 December 2020 | - | ||
| Net Book Value | |||
| 31 December 2020 | - | ||
| 31 December 2019 | 2,932 | ||
| 12. | FIXED ASSET INVESTMENTS | ||
| 18 month period | |||
| Year ended | ended | ||
| 31 | 31 December | ||
| December | 2019 | ||
| 2020 | £ | ||
| £ | |||
| Market value | |||
| At 1 January 2020 | 789,311 | 940,975 | |
| Additions | 793,295 | 440,962 | |
| Disposals | (793,295) | (657,202) | |
| Cash movement | - | (4,277) | |
| Gains | 16,020 | 68,853 | |
| Transferred to Bowel Research UK | (805,331) | - | |
| At 31 December 2020 | - | 789,311 |
24
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
13. DEBTORS
| EBTORS | ||
|---|---|---|
| 18 month | ||
| Year ended | period ended | |
| 31 | 31 December | |
| December | 2019 | |
| 2020 | £ | |
| £ | ||
| Other debtors | - | 3,402 |
| Accrued income | 695,501 | 642,048 |
| Prepayments | - | 51,663 |
| 695,501 | 697,113 |
14. CREDITORS : amounts falling due within one year
| 18 month | |||
|---|---|---|---|
| Year ended | period ended | ||
| 31 | 31 December | ||
| December | 2019 | ||
| 2020 | £ | ||
| £ | |||
| Trade creditors | - | 43,650 | |
| Deferred Income | - | 7,500 | |
| Accruals | - | 6,500 | |
| Social Security and other taxes | - | 18,580 | |
| Grants payable | - | 978,983 | |
| - | 1,055,213 | ||
| 15. | CREDITORS : amounts falling due after more than one year | ||
| 18 month | |||
| period ended | |||
| Year ended | 31 December | ||
| 31 | 2019 | ||
| December | |||
| 2020 | |||
| £ | £ | ||
| Grants payable | - | 480,505 |
25
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
16A. NET ASSETS OF THE FUNDS OF THE CHARITY
The charity’s net assets belong to the various funds as follows:
| As at 31 December 2020 Restricted funds Designated funds Unrestricted funds Total As at 31 December 2019 Restricted funds Designated funds Unrestricted funds Total |
Fixed Assets Net Current Assets Long Term Liabilities £ £ £ - - - - - 695,501 - - - - 695,501 - - - 792,243 375,881 716,271 (368,059) (220,431) (260,074) - 792,243 724,093 (480,505) |
Fund Balances £ - - 695,501 695,501 155,450 456,197 424,184 |
Fund Balances £ - - 695,501 695,501 155,450 456,197 424,184 |
|---|---|---|---|
695,501 |
|||
155,450 456,197 424,184 |
|||
| 1,035,831 |
26
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
16B. RESTRICTED FUNDS: MOVEMENTS IN THE PERIOD
| For the year ended 31 December 2020 1 PhD fund PhD fund – Ulcerative Colitis Role of Adam17 in the gut Lucy Thomas Fund Graham Kirkham Foundation K McDonald General Charitable Trust G S Plaut Morrison Masonic charitable Fund Total For the period ended 31 December 2019 PhD fund PhD fund – Ulcerative Colitis Role of Adam17 in the gut Phd Patrons Fund Pseudo Obstruction Research Phd Stress on IBD Masonic Charitable Fund Lucy Thomas Fund John Moulton Garfield Weston Patrick and Helena Frost Foundation Frognall trust Graham Kirkham Foundation K McDonald General Charitable Trust The Hilary Awdry Charitable Trust Mrs Iris Noreen Setchell Charitable Trust Total |
January 2020 £ 65,169 49,726 3,813 11,742 12,500 12,500 - - - 155,450 1 July 2018 £ 74,169 49,726 3,813 - 25,000 25,000 25,000 76,462 - - - - - - - - 279,170 |
Income Expenditure Transfers 31 December 2020 £ £ £ £ - - (65,169) - - - (49,726) - - - (3,813) - - - (11,742) - - - 1,000 1,800 75,000 (7,500) (7,500) - - - (5,000) (5,000) (1,000) (1,800) (75,000) - - - - - 77,800 (15,000) (218,250) - Income Expenditure Transfers 31 December 2019 £ £ £ £ - - (9,000) 65,169 - - - 49,726 - - - 3,813 25,000 - (25,000) - 117,042 (142,042) - - - (25,000) - - 50,000 (75,000) - - 12,273 (76,993) - 11,742 70,000 (70,000) - - 22,500 (22,500) - - 30,000 - (30,000) - 5000 - (5,000) - 12,500 12,500 1,000 - - - - - (1,000) 12,500 12,500 - 5,000 - (5,000) - 362,815 (411,535) (75,000) 155,450 |
|---|---|---|
27
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
16B. RESTRICTED FUNDS: MOVEMENTS IN THE YEAR (continued)
Donors of the above funds directed the income specifically to the activities outlined below. Where funds are carried forward these will be directed as to their specific requests next year.
The PhD fund was originally formed to support the infrastructure and research work within the National Bowel Research Centre. This has now been committed to funding the PhD programme.
The PhD fund – Ulcerative Colitis was given by the Davidson Family Trust. This covers the cost of a PhD student and associated costs for 3 years for a project dedicated to Ulcerative Colitis.
The Role of Adam17 project took place during the previous year. The remainder will be transferred to a project that covers similar work.
The Masonic Charitable Foundation is the start of a 3 year grant totalling £225,000 which will support the work of 3 Phds. This is an exciting fund and shows how responsive Trusts are to our research programme.
The Lucy Thomas fund is to provide research into the BRAF gene and its role in bowel cancer in memory of Lucy Thomas who sadly died in 2017. The fund has been raised by family and friends who have carried out various events and challenges.
The funds from Graham Kirkham Foundation and K Mcdonald General Charitable Trust are to support a trial of the Bowel Buddies project, this is a new project aimed at connecting patients who have recently been through surgery to be befriended by someone who has also been through a similar procedure.
The income from G S Plaut and Morrison Trust has been received against projects that were agreed in previous years with expenditure being met from the PhD fund NCBRSI. As a result we have been able to transfer the equivalent value back into the fund. We will now repurpose these funds to additional new research.
The transfer of funds relates to income towards grants that have already been awarded. Once funding for a grant is agreed by our Grants committee we follow accounting rules which state that we must show the full cost immediately even if the grant spans over 3 years. We may then, as above, receive specific income against these grants which we have to show as received.
Following the transfer of the assets to Bowel Research UK at 30[th] September 2020 all of the restricted funds were transferred over to the new charity and were again restricted in line with the donor’s wishes.
28
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
16C. UNRESTRICTED FUNDS: MOVEMENTS IN THE YEAR
| For the period ended 31 December 2020 General funds |
1 January 2020 £ 424,184 |
Income Expenditure £ £ 454,999 (322,122) |
Gains Transfer 31 December 2020 £ £ 16,020 122,420 695,501 |
|---|---|---|---|
General funds comprise those funds which the Trustees are free to use in accordance with the charitable objects.
| For the period ended 31 December 2019 General funds |
1 July 2018 £ 377,142 |
Income Expenditure £ £ 1,411,6 62 (783,473) |
Transfer/ Gains 31 December 2019 £ £ (581,147) 424,184 |
Transfer/ Gains 31 December 2019 £ £ (581,147) 424,184 |
|---|---|---|---|---|
16D. DESIGNATED FUNDS: MOVEMENTS IN THE PERIOD
| For the year ended 31 December 2020 Future PhD funds For the period ended 31 December 2019 Future PhD funds |
1 January 2020 £ 456,197 1 July 2018 £ 360,474 |
Income Expenditure £ £ - - Income Expenditure £ £ - (629,277) |
Transfer/ Gains 31 December 2020 £ £ (456,197) - Transfer/ Gains 31 December 2019 £ £ 725,000 456,197 |
|---|---|---|---|
29
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
17. RECONCILIATION OF NET INCOME TO NET CASH FLOWS FROM OPERATING ACTIVITES
| Net income for the reporting period (as per statement of financial activities) Adjustments for: (Gains) on investments Dividends and interest from investments Depreciation charges Decrease/(increase) in debtors (Decrease)/Increase in creditors Net cash provided by operating activities 18. ANALYSIS OF NET FUNDS Cash at Bank and in Hand |
Year ended 31 December 2020 18 month period ended 31 December 2019 £ £ 211,697 19,045 (16,020) (19,170) 998 (68,853) (46,399) 999 1,612 (472,124) (1,535,718) 511,126 (1,356,601) (56,206) 1 January Cash 31 December 2020 Flows 2020 £ £ £ 1,082,193 (1,082,193) - |
|---|---|
19. RELATED PARTY TRANSACTIONS
Professor Charles Knowles is a Trustee of Bowel & Cancer Research and is Director of the National Bowel Research Centre. It is a policy of the charity to have a Director of the National Bowel Research Centre on its Board. Paul Reynolds, Asha Senapati and Richard Pertwee are also Trustees of Bowel Research UK. There were no other related party transactions in the year.
30
BOWEL & CANCER RESEARCH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020
20. PENSION
The charity runs a pension scheme with NEST to cover its obligations under Auto- Enrolment. This is a defined contribution scheme, alternatively employees can elect to have their pension contributions paid into a private pension scheme. Employer contributions to pension plans in the period were £5,783 ( 2019: £10,926 ). The total value of contributions included within creditors at the period end was £nil (2019: £410 )
21. FINANCIAL INSTRUMENTS
| Year ended | 18 month period ended | |
|---|---|---|
| 2020 | 2019 | |
| £ | £ | |
| Financial assets | ||
| Financial assets measured at fair value | - | 789,311 |
Financial assets measured at fair value comprise listed investments.
22. TRANSFER OF ASSETS
On 30 September 2020 the trade and assets were transferred to Bowel Research UK. The net transfer of £539,009 comprised tangible fixed assets £2,508, fixed asset investments £805,331, debtors £97,386, cash at bank £760,870, creditors £64,546 and grant commitments of £1,062,540.
23. ULTIMATE CONTROLLING PARTY
From 31 May 2020 Bowel Research UK acquired control of the Charity by virtue of a signed Hive Up agreement. Bowel Research UK is a Charitable Incorporated Organisation registered in England and Wales with Charity Commission number 1186061. Consolidated financial statements are available from the registered office address; C/O Royal College of Surgeons, Lincoln’s Inn Fields, London, WC2A 3PE.
31